share_log

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

摩根士丹利以增持评级启动对Continueum Therapeutics的报道,宣布目标股价为25美元
Benzinga ·  04/30 05:15

Morgan Stanley analyst Jeffrey Hung initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and announces Price Target of $25.

摩根士丹利分析师洪杰弗里以增持评级启动了对Contineum Therapeutics(纳斯达克股票代码:CTNM)的报道,并宣布目标股价为25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发